Evidence map›Paper›PMID 35291291›Full record

ArticlebioRxiv : the preprint server for biology2022

Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease.

Panpan Zhou, Ge Song, Wan-Ting He, Nathan Beutler, Longping V Tse, David R Martinez, Alexandra Schäfer, Fabio Anzanello, Peter Yong, Linghang Peng and 20 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 23 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors at 4 institutions in 1 country.

Panpan ZhouDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Ge SongDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Wan-Ting HeDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Nathan BeutlerDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Longping V TseDepartment of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
David R MartinezDepartment of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Alexandra SchäferDepartment of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Fabio AnzanelloDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Peter YongDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Linghang PengDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Katharina DuekerDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Rami MusharrafiehDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Sean CallaghanDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Tazio CapozzolaDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Meng YuanDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Hejun LiuDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Oliver LimboIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Mara ParrenDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Elijah GarciaDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Stephen A RawlingsDivision of Infectious Diseases, Department of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.
Davey M SmithDivision of Infectious Diseases, Department of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.
David NemazeeDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Joseph G JardineIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Ian A WilsonIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Yana SafonovaDepartment of Computer Science, Johns Hopkins University, Baltimore, MD 21218, USA.
Thomas F RogersDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Ralph S BaricDepartment of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Lisa E GralinskiDepartment of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Dennis R BurtonDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Raiees AndrabiDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Scripps Research Institute · USUniversity of North Carolina at Chapel Hill · USUniversity of California San Diego · USJohns Hopkins University · US

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
Project 3: Serological Interactions with the Mucosal Innate Immune System Regulates COVID-19 Associated Tissue Damage.U54CA260543 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WOLFGANG, MATTHEW C · 2020 to 2024
$9.8M
HOPE Training GrantT32AI007384 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Sara Gianella Weibel, Scott L Letendre · 1990 to 2026
$9.7M
Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0M
Combining germline-targeting, B cell immunofocusing and Env-Ab coevolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodiesR61AI161818 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ANDRABI, RAIEES AHMAD, SHAW, GEORGE M · 2021 to 2023
$4.7M
Identifying Genetic Regulators and New Models of Wild Type Coronavirus PathogenesisR21AI145372 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GRALINSKI, LISA · 2020 to 2021
$389k
NCI NIH HHS U54 CA260543NIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI157155NIAID NIH HHS R21 AI145372NIAID NIH HHS R61 AI161818NIAID NIH HHS T32 AI007384
6 · The paper itself

Abstract

Pan-betacoronavirus neutralizing antibodies may hold the key to developing broadly protective vaccines against coronaviruses that cause severe disease, for anticipating novel pandemic-causing viruses, and to respond more effectively to SARS-CoV-2 variants. The emergence of the Omicron variant of SARS-CoV-2 has illustrated the limitations of solely targeting the receptor binding domain (RBD) of the envelope Spike (S)-protein. Here, we isolated a large panel of broadly neutralizing antibodies (bnAbs) from SARS-CoV-2 recovered-vaccinated donors that target a conserved S2 region in the fusion machinery on betacoronavirus spikes. Select bnAbs show broad

Identifiers

PMID35291291
PMCPMC8923106
OpenAlexW4220743812

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.